Sphingosine kinase type 1 inhibitors
US9388121B2 · kind B2 · utility
14Cited by
5References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 11, 2012 |
| Grant date | Jul 12, 2016 |
| Priority date | — |
| Expiry date | Feb 19, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D295/092
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.